Teva Pharmaceutical Industries Ltd. Press Releases https://ir.tevapharm.com/generated by Q4Tue, 15 Sep 2026 11:06:39 -0400Copyright Q4 Inc. All rights reserved.Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy265f83af-78b9-41a7-b75a-288e2b479e8ahttps://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Begins-Trading-Ordinary-Shares-Directly-on-the-NYSE-Marking-a-Milestone-in-its-Pivot-to-Growth-Strategy/default.aspxMon, 14 Sep 2026 08:03:00 -0400Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notesa43b90dd-c558-4320-a496-2bd207d09357https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Announces-Successful-Pricing-of-4-9-billion-Equivalent-Senior-Notes/default.aspxThu, 10 Sep 2026 06:04:00 -0400Teva Announces Launch of Offering of Senior Notes9ab2d136-307b-4f51-865b-58db7c26a5f2https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/TevaAnnouncesLaunchofOfferingofSenior-Notes/default.aspxMon, 07 Sep 2026 03:53:00 -0400S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline51d92888-4461-427a-b0c9-c712faefaca3https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/SP-Global-Ratings-Upgrades-Teva-to-BBB--Marking-Third-Credit-Rating-Upgrade-in-Recent-Months-and-Reflecting-Strong-Execution-and-Financial-Discipline/default.aspxFri, 04 Sep 2026 11:30:00 -0400Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential738ba528-4a2d-4d0a-a1ee-46a67917eb68https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Announces-Positive-Topline-Results-from-Phase-2a-Study-in-Celiac-Disease-for-Its-Anti-IL-15-Antibody-Further-Validating-Its-Pipeline-in-a-Product-Potential/default.aspxWed, 02 Sep 2026 07:03:00 -0400Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September2fb70842-aad3-4add-aaf6-05d9e6f99e0dhttps://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-Present-at-Morgan-Stanley-J-P--Morgan-and-BofA-Investor-Conferences-in-September/default.aspxTue, 01 Sep 2026 16:30:00 -0400Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.70b93988-7a3d-4a6a-8dfe-00d23e7aa752https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-and-Trump-Administration-Announce-Intent-to-Reach-Agreement-around-Affordable-Medicines-and-Supply-Chain-Security-for-Patients-in-the-U-S-/default.aspxMon, 31 Aug 2026 16:06:00 -0400Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy 2c63b8de-e885-4be5-a5d4-22266dc04170https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/TevaAnnouncesProposedAcquisition-ofaNovel-NeuroscienceProductReinforcing-Disciplined-Business-Development-Approach-Under-Pivot-to-Growth-Strategy/default.aspxFri, 28 Aug 2026 06:17:00 -0400U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome898fa882-5c1f-4ed9-b2ec-990671eaf953https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/U-S--FDA-Accepts-Tevas-New-Drug-Application-NDA-and-Grants-Priority-Review-for-Ecopipam-a-First-in-Class-Investigational-Therapy-for-Pediatric-Patients-with-Tourette-Syndrome/default.aspxWed, 19 Aug 2026 08:30:00 -0400Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy9e3883ee-6bbd-4a3d-bd04-ef596d826e56https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Moodys-RatingsUpgrades-Teva-to-Investment-GradeReflecting-theOngoingExecutionofPivottoGrowthStrategy/default.aspxTue, 11 Aug 2026 08:00:00 -0400